“Adoption of Continuous Flow Processes in Pharmaceutical Manufacturing”
- Continuous flow chemistry significantly reduces reaction times and enhances heat and mass transfer compared to traditional batch processing—making it highly attractive for pharmaceutical companies seeking cost and time efficiency.
- Regulatory bodies like the U.S. FDA and EMA are encouraging the use of continuous manufacturing in drug production due to its improved product consistency and reduced contamination risks.
- Flow chemistry systems allow seamless scale-up from lab to industrial scale with minimal revalidation, ideal for agile drug development and small-batch specialty medicines.
- For instance, in 2023, Pfizer and GSK reported expanded use of flow chemistry systems in small-molecule API production, citing improved yield and sustainability. Additionally, Snapdragon Chemistry (acquired by Cambrex) is developing continuous flow solutions for pharma innovators
- As pharmaceutical manufacturers push for faster, greener, and more controllable production methods, the adoption of continuous flow chemistry is becoming a foundational trend driving the global market’s growth.
